By using our site you consent to the CTFN Privacy Policy, Cookies Policy, and Terms of Service.


Aetna/CVS Review Advances at DOJ

A decision in the Aetna/CVS Health merger is likely to come in the next three to six weeks, according to a former assistant section chief in the healthcare and consumerfeatured

Pondering the Time Warner/AT&T Legal Drama

The U.S. Department of Justice filed an appeal on July 12 seeking to overturn thefeatured

Vertical Issues and IP Will be Focus for EC in Gemalto/Thales Case

With additional reporting by Rachel Rigby – Thales is a large client for the encryption key management tools provided by Gemalto, and therefore the merger of the twofeatured

NxStage/Fresenius Review Lingers at FTC

Fresenius and NxStage are several months into a timing agreement with the Federal Trade Commission as the agency continues its review of the companies’ pendingfeatured

Linde and Praxair Continue to Work with Colombian Regulator

Industrial gas giants Linde and Praxair have filed an appeal with Colombian antitrust regulator Superintendencia de Industria y Comercio (SIC) to clarify the terms of the remediesfeatured

DOJ Review of Rockwell Collins/United Technologies Seen Concluding Later in Third Quarter

Antitrust sources told CTFN that they expect the Department of Justice’s review of the Rockwell Collins/United Technologies merger to conclude later in the third quarter.featured

DOJ Document Review of Aetna/CVS Deal Drawing to Close

The Department of Justice is well into its document review and is wrapping up the interview process with CVS Health’s $69 billion acquisition of Aetna, a personfeatured

Competing Bids for Linde/Praxair Divestitures in Europe

With additional reporting by Valeria Camerino – Taiyo Nippon Sanso and Messer are most likely in pole position for the disposals that Linde and Praxair will need to makefeatured

Orbotech/KLA-Tencor Deal Drawing Regulatory Interest in Korea

KLA-Tencor’s planned $3.4 billion takeover of Israeli rival Orbotech is drawing interest in Korea, a Seoul-based antitrustfeatured

No Remedies Expected in A. Schulman/LyondellBasell Deal

LyondellBasell’s takeover of A. Schulman will not require a Phase I extension or any remedies from the European Commission’s reviewfeatured


Interested in a trial?

Simply fill out the form below and one of our representatives will be in touch.